Comparative Pharmacology
Head-to-head clinical analysis: BELBUCA versus ORAMORPH SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELBUCA versus ORAMORPH SR.
BELBUCA vs ORAMORPH SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial mu-opioid receptor agonist; produces analgesia by binding to mu-opioid receptors in the CNS, with ceiling effect on respiratory depression.
Morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. Binding to mu-opioid receptors in the central nervous system (CNS) and peripheral tissues results in analgesia, euphoria, sedation, respiratory depression, and physical dependence. Morphine also activates descending inhibitory pathways and inhibits ascending nociceptive transmission.
Apply one buccal film to inner cheek every 12 hours. Initiate at 75 mcg once daily or every 12 hours for opioid-experienced patients; titrate in increments of 75-150 mcg every 4 days. Maximum dose: 900 mcg every 12 hours.
10-30 mg orally every 8-12 hours, sustained-release; titrate as needed for pain.
None Documented
None Documented
Terminal elimination half-life of buprenorphine is approximately 24-42 hours, allowing for twice-weekly dosing of BELBUCA.
2–4 hours in adults; in controlled-release formulation, effective half-life is prolonged due to sustained absorption. Clinically, steady-state is achieved in 1–2 days.
Primarily renal (70-80% as metabolites, ~15% as unchanged buprenorphine); biliary/fecal excretion accounts for ~10-20%.
Renal (approximately 90% as morphine-3-glucuronide and morphine-6-glucuronide, minor amounts of unchanged morphine, and other conjugates); biliary/fecal (approximately 10%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic